*Department of Psychiatry, University of Kansas School of Medicine-Wichita
†Clinical Research Institute, Wichita, Kansas
He has more than 30 years of drug development research experience at all levels (ie, preclinical through Phase IV) and has been a principal investigator on over 250 clinical trials including every antidepressant marketed in the United States over the last 25 years. Dr. Preskorn maintains a website at 〈www.preskorn.com〉 where readers can access previous columns and other publications.
Disclosure statement: Dr. Preskorn, as chief executive officer of the Clinical Research Institute, Wichita, KS, and, in many cases, as principal investigator, has received grants from the following entities: AstraZeneca, Biovail, Boehringer-Ingelhaim, Bristol-Myers Squibb, Comentis, Cyberonics, Eisai, EnViVo, GlaxoSmithKline, Merck, Memory, Organon, Otsuka, Pfizer, Sepracor, Somerset, Wyeth, and the National Institute of Mental Health. He has served as a consultant, on the advisory board, and/or as a speaker for the following: Biovail, Bristol-Myers Squibb, Comentis, Covedien, Cyberonics, Eli Lilly, EnViVo, Evotec, Fabre-Kramer, Jazz, Memory, Organon, Pfizer, Somerset, Transcept, and Wyeth.